| Protocol No. | 12551 | Principal Investigator | Friedlander, Terence |
| Phase | II (Cancer Control) |
| Age Group | Adult | Scope | National |
|
| Title | A Phase II Study of Increased-Dose Abiraterone Acetate in Patients with Castration Resistant Prostate Cancer |
| Objective | To determine the PSA response proportion to increased-dose abiraterone for patients who experienced disease progression following standard dose abiraterone therapy |
|
|
| Key Eligibility | Males, Age: 18+
* Have histologically confirmed adenocarcinoma of the prostate.
* No prior therapy with chemotherapy for metastatic prostate cancer. |
| Applicable Disease Sites | Prostate |
|
|
|
| Status | Open |
| Participating Institutions | Knight Cancer Institute
Mt. Zion : Rebecca Cook
Oregon Health & Science University |
|
| Eligibility Document | 12551_CTGovEligibility_ NCT01637402.doc |
|
| Contact | Rebecca Cook |
Phone:415-885-3557
Pager:
Email:CookR@cc.ucsf.edu |